Riskpilot← Back to searchSign inGet full accessDNA TRACER TECHNOLOGIES AS
ASActiveOrg 998784484Bygdøy Allé 2, 0257 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20121 employees
Revenue 2024
NOK 1,5M
-45% vs 2023
EBITDA margin
-55.6%
-41435% vs 2023
Equity ratio
-15.5%
Financial strength
Net profit 2024
NOK -826K
-152447% vs 2023
| Revenue | NOK 1,5M | -45% |
| EBITDA | NOK -826K | -41435% |
| Net profit | NOK -826K | -152447% |
| Total assets | NOK 4,8M | +365% |
| Equity | NOK -747K | -1048% |
| Employees | 1 | — |
Legal name
DNA TRACER TECHNOLOGIES AS
Org number
998784484
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3. september 2012
Share capital
NOK 37 287
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Annen forskning og annet utviklingsarbeid innen naturvitenskap og teknikk.
Address
Bygdøy Allé 2, 0257 Oslo
Email
info@wellgenetics.net
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 259 | 1 910 | 3 625 | 2 688 | 1 485 |
| Staff expenses | −453 | −21 | −17 | −0 | −8 |
| EBITDA | 601 | 1 476 | −963 | −2 | −826 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 601 | 1 476 | −963 | −2 | −826 |
| Net financials | −133 | 0 | −3 | 3 | 0 |
| Profit before tax | 468 | 1 476 | −966 | 1 | −826 |
| Tax | 12 | −0 | −0 | −0 | −0 |
| Net profit | 456 | 1 476 | −966 | 1 | −826 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 388 | 3 454 | 1 532 | 1 035 | 4 816 |
| Equity | −2 314 | 1 044 | 78 | 79 | −747 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 702 | 2 410 | 1 454 | 956 | 5 563 |
| Total debt | 3 702 | 2 410 | 1 454 | 956 | 5 563 |
EBITDA margin
-55.6%
This company
15.8%
Market median
-452% vs market
20202024
Equity ratio
-15.5%
This company
38.2%
Market median
-141% vs market
20202024
Return on equity
-82572000.0%
This company
18.4%
Market median
-448760970% vs market
20202024
Net profit margin
-55.6%
This company
8.1%
Market median
-786% vs market
20202024
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
20202024
Debt / equity
7.45×
This company
0.62×
Market median
-1102% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Chairman | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 74.85% | 74.85% | 2022 | |
| Company | 7.9% | 7.9% | 2022 | |
| Company | 3.34% | 3.34% | 2022 | |
| Individual | 2.8% | 2.8% | 2022 | |
| Company | 2.71% | 2.71% | 2022 | |
| Company | 2.11% | 2.11% | 2022 | |
| Individual | 1.97% | 1.97% | 2022 | |
| Company | 1.61% | 1.61% | 2022 | |
| Company | 1.05% | 1.05% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oseng As
DNA TRACER TECHNOLOGIES AS Board members of DNA TRACER TECHNOLOGIES AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ørjan Olsvik | Board of Directors | 0 companies |
| Harald Johan Norvik | Board of Directors | 0 companies |
| Odd Ingar Skaug | Board of Directors | 0 companies |
| Dag Haugse | Chairman | 0 companies |